Glp-1 Drugs

Below both sides: the key questions, where they part ways and how each answer holds up

Mainstream views

Proven efficacy for diabetes and weight loss

GLP-1 receptor agonists such as semaglutide, liraglutide and tirzepatide (a dual GLP-1/GIP agonist) mimic gut hormones. They increase insulin secretion, suppress glucagon, slow gastric emptying and reduce appetite. Large randomized trials (STEP, SURMOUNT, SUSTAIN) show average weight loss of about 15% with semaglutide 2.4 mg and about 20% or more with higher-dose tirzepatide. Glycemic control improves too. Regulators and medical societies now treat obesity as a chronic disease that these drugs can manage. A full list of approved brands is at drugs.com.

Broader cardiometabolic benefits

Outcome trials show benefits beyond weight. SELECT found that semaglutide cut major adverse cardiovascular events by about 20% in overweight adults with existing heart disease and no diabetes. Other trials show benefits for kidney disease (FLOW), heart failure with preserved ejection fraction, and sleep apnea. Newer agents such as retatrutide are reported to ease knee osteoarthritis symptoms, and Lilly is expected to seek approval in early 2027. Observational data suggest that stopping therapy is linked to more cardiovascular events in people with diabetes, which supports long-term use. Weight is typically regained after discontinuation, so obesity is generally viewed as needing ongoing treatment.

Real risks, access and cost concerns

Mainstream experts also stress the downsides. Common side effects are nausea, vomiting, diarrhea and constipation. Rarer risks include pancreatitis, gallbladder disease and gastroparesis. Recent reporting describes a new label warning for a rare eye complication, with roughly 2.6 extra cases per 100,000 person-years (substack.com). Muscle loss, cost, insurance coverage, supply, and unsupervised compounded versions remain major issues. Clinicians advise using the drugs with nutrition, exercise and medical supervision, and weighing benefits against risks for each patient.

Conclusion

The mainstream view is that GLP-1 drugs are among the most significant advances in treating diabetes and obesity. They have strong evidence for weight loss and cardiometabolic benefit, and the list of indications is growing. They are not a cure-all. They need long-term use, they carry side effects and rare safety signals that are still being monitored, and cost and access limit who can use them.

Alternative views

Lifestyle and food-environment first, not drugs

Some public health scholars say GLP-1s treat a symptom of an obesogenic food system. They worry the drugs let policymakers and industry avoid harder fixes such as limits on ultra-processed food marketing, better school meals and urban design. Critics also say the drugs risk becoming a substitute for nutrition and exercise, and that they are increasingly used for cosmetic weight loss. A harvard.edu Harvard public health piece describes these skeptic critiques of cost, side effects and cosmetic use, though it ultimately weighs them against the drugs' benefits.

Attributed to: Skeptics summarized in a Harvard T.H. Chan School of Public Health alumni perspective. I can't name specific individual proponents of the food-system argument from that source.

Long-term safety is under-studied and risks are underplayed

This view holds that mass adoption is running ahead of long-term evidence. New signals keep appearing, including a recently reported eye-complication warning at roughly 2.6 extra cases per 100,000 person-years (substack.com). Earlier concerns include gastrointestinal harms, muscle and bone loss alongside fat loss, and rebound weight gain after stopping. Proponents argue that millions of people will take these drugs for decades, so small per-patient risks matter at population scale and the trials were too short to capture them. Others add that observational data can't settle questions of causation.

Attributed to: Raised by regulators and drug-safety researchers through label updates. I'm not certain of named individual advocates for the strongest version.

Access and cost make it an equity and system-affordability problem

A health-economics view argues the drugs may be effective but unaffordable at scale. List prices have averaged around $12,000 a year, and many insurers restrict coverage. If tens of millions of eligible adults were covered, budgets for Medicare and employers could be strained, while the people with the greatest need go without. Some argue price cuts, generics abroad and compounded versions are therefore justified. Others argue coverage should prioritize diabetes and cardiovascular patients. Employer-benefit analysts note that continued coverage for diabetes is clinically valuable, because stopping is associated with more cardiovascular events.

Attributed to: Employer-coverage commentators such as the Employer Coverage Substack, and health-policy analysts generally. I can't attribute this to specific named individuals with confidence.

Body-positive and anti-diet critique of medicalizing weight

Fat-acceptance and Health at Every Size advocates argue GLP-1s reinforce weight stigma by treating body size as the disease. They stress that weight cycling and drug dependence may be harmful, that BMI is a crude measure, and that health improvements can come from behavior changes without weight loss. They also worry about eating-disorder risk and social pressure to be thin. In its strongest form, the claim is that medicine should target metabolic outcomes, not weight itself.

Attributed to: Health at Every Size advocates and anti-diet dietitians, with the movement associated with Lindo Bacon and Linda Bacon's work. Individual positions on GLP-1s vary.

The key questions

Where they part ways, and how each answer holds up. An answer stands or falls on what it explains and how it survives criticism, not on who holds it.

Add a tint

A tint shows how one school of thought would answer these questions. The two views stay as they are.

  • Is the long-term safety evidence good enough to justify wide use now?

    Mainstream: Trial and outcome data show benefits that outweigh known risks, and rare signals are being caught and monitored through label updates.

    Alternative: Adoption is outrunning evidence, so small per-patient risks may add up to real harm across millions of people over decades.

    The mainstream answer holds up better, for now. The mainstream answer is tied to measured benefits and measured rare risks, while the alternative cannot name a harm that has appeared at a size large enough to change the balance.

    How each answer holds up

    What it explains

    Mainstream: It accounts for reduced heart events, kidney outcomes and the small size of the newly found eye risk.

    Alternative: It accounts for why safety signals such as the eye complication keep appearing after approval.

    What would prove it wrong

    Mainstream: Large, long follow-up studies showing harms that outweigh benefits, such as excess cancers, bone fractures or vision loss, would count against it. The eye signal has been seen, but at a rate of a few cases per 100,000 person-years it is small next to the benefits in high-risk groups.

    Alternative: Long-term follow-up showing no excess of serious harms beyond the already-labelled ones would count against it. So far the new signals are rare and small, and no large unexpected harm has appeared.

    Weak spot

    Mainstream: The benefit evidence comes mostly from people with diabetes or existing heart disease, and it is then applied to healthier people who would take the drugs for decades. Data on muscle and bone loss and on stopping and restarting are thin.

    Alternative: The claim names no specific harm of a size that outweighs the proven benefits, so it fits almost any result. Calling the trials too short, without saying what they missed, is a loose assumption.

  • Should the response to obesity put food environment and lifestyle first, ahead of drugs?

    Mainstream: Treat obesity as a chronic disease with drugs alongside nutrition and exercise, because lifestyle alone rarely produces or keeps large weight loss.

    Alternative: Fix the food system through marketing limits, school meals and urban design, and treat the drugs as a distraction.

    Still open. Larger trials of food-policy measures with measured weight outcomes, alongside real-world drug adherence data, would show which does more per dollar.

    How each answer holds up

    What it explains

    Mainstream: It accounts for the size of weight loss in the trials and for the regain after lifestyle-only programs and after stopping the drugs.

    Alternative: It accounts for why obesity rose across whole populations, which individual willpower or drugs cannot explain.

    What would show it failing

    Mainstream: The policy would fail if people on drugs did no better than people on lifestyle care, or if adherence collapsed. Adherence is often poor in real use, though outcomes are still better than lifestyle alone.

    Alternative: It would fail if population-level food policies produced little measurable change in obesity. Such policies have had modest effects so far, such as sugar taxes.

    Weak spot

    Mainstream: Heavy reliance on drugs may be unaffordable for health systems, and it does nothing about the food environment that drives weight gain.

    Alternative: It sets drugs against food policy as if they were alternatives, yet the two can be done together. It also has no answer for the people who already have obesity now.

  • Do the drugs create a cost and access problem that should change how they are covered?

    Mainstream: Cost and coverage are serious problems, but the drugs should still be offered to patients with a clear medical need.

    Alternative: Cover diabetes and heart patients first, and cut prices through generics or compounding, because universal coverage would strain budgets.

    Still open. Real-world cost data on complications avoided and on how far prices fall would settle whether wide coverage is affordable.

    How each answer holds up

    What it explains

    Mainstream: It accounts for the gap between proven benefit and who actually gets the drugs.

    Alternative: It accounts for the budget pressure on Medicare and employers and for the observed insurer restrictions.

    What would show it failing

    Mainstream: It would fail if spending on the drugs grew without any offsetting drop in complications. Savings from fewer heart events and kidney problems have been shown for some groups but not for all.

    Alternative: It would fail if prices fell sharply and coverage became affordable. Prices are falling, so this may be partly undone.

    Weak spot

    Mainstream: It names cost as a major issue but offers no rule for who comes first.

    Alternative: Backing compounded versions conflicts with safety concerns about unsupervised products, which this same side raises elsewhere.

  • Is treating weight itself as the disease the right approach?

    Mainstream: Obesity is a chronic disease and reducing weight is a legitimate medical goal.

    Alternative: Medicine should target metabolic outcomes rather than weight, to avoid stigma and weight cycling.

    A question of values. The mainstream side weighs the health gains from weight loss more heavily, while the alternative side weighs stigma, body autonomy and the risk of eating disorders more heavily.

Where they agree

  • GLP-1 drugs produce substantial weight loss and better blood sugar control in randomized trials.
  • Side effects such as nausea and rare serious risks exist, including a newly flagged eye complication.
  • Weight usually comes back after stopping, and cost and access limit who can use the drugs.
  • Medical supervision and attention to nutrition and muscle loss matter during treatment.

Your verdict

Which side made the stronger case?
Did reading both sides change your mind?

Your badge

Read both sides to the end and earn a badge to share. Most people never open the other one.

  • Mainstream
  • Alternative

References

  • Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
  • Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
  • Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
  • Perkovic V et al. Effects of semaglutide on chronic kidney disease in type 2 diabetes (FLOW). N Engl J Med. 2024;391:109-121.
  • American Diabetes Association. Standards of Care in Diabetes. Diabetes Care (current edition).
  • GLP-1 Drugs (GLP-1 Agonist) - List of Brands & Generics
  • Comparing Ozempic, Wegovy and Other GLP-1 Drugs - GoodRx

Comments

No comments yet. Be the first to comment!